MedTrace Logo

Ketamine for Relapse Prevention in Recurrent Depressive Disorder

NCT02661061 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2020-01-13

Study results available
· View outcomes & findings →

Summary

Randomised, controlled, parallel-group, pilot clinical trial of ketamine vs. midazolam for depression relapse prevention in persons at high risk. The main purpose of the pilot study is to assess trial processes to help inform a future definitive trial.

Conditions

Interventions

DRUG

Ketamine

A sub-anaesthetic dose of ketamine will be administered in four infusions, each two weeks apart.

DRUG

Midazolam

A sub-anaesthetic dose of midazolam will be administered in four infusions, each two weeks apart.

Sponsors & Collaborators

  • St Patrick's Hospital, Ireland

    lead OTHER

Principal Investigators

  • Declan McLoughlin · University of Dublin, Trinity College

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-05-23
Completion
2018-05-23

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02661061 on ClinicalTrials.gov